Table 5 Results of studies that reported dysregulation of miR-1908 in clinical samples from cancers (ANCTs: adjacent non-cancerous tissues, OS: overall survival, DFS: disease-free survival, TNM: tumor node metastasis, PFS: progression-free survival, HGSOC: high‐grade serous ovarian carcinoma)

Breast cancer

TCGA dataset

50 pairs of tumor tissues and ANCTs

60 breast cancer patients compared to 60 healthy controls

Up

(Younger breast cancer patients and those with HER2-positive tumors had a higher levels of this miRNA)

–

–

age and her-2 status

[5]

Cervical cancer

GSE63514

36 pairs of tumor tissues and ANCTs

up

Shorter OS

–

–

[6]

Chordomas

3 chordomas tissues and 3 notochord tissues

Down

–

–

–

[22]

Glioblastoma

47 glioma patients and five normal brain samples

Up

Shorter OS and DFS

–

–

[7]

Glioma

GEO and TCGA databases

Up

Shorter OS and DFS

–

–

[8]

Nasopharyngeal carcinoma

10 NPC patients and 10 healthy controls

Up

–

–

–

[10]

Osteosarcoma

212 pairs of tumor tissues and ANCTs

Up

Shorter OS

–

Metastasis, poorer chemotherapy response and greater extent of recurrence

[23]

Osteosarcoma

46 osteosarcoma samples and 9 normal muscle samples

Up

Shorter OS

–

Advanced TNM stage and tumor growth

[12]

Ovarian cancer

TCGA dataset (491 patients with OC)

Down

Better OS and DFS

miR-1908 expression level was found to be an independent predictor of OS of patients with OC and its expression was associated with age

–

[24]

Ovarian cancer

175 patients with HGSOC

GSE106817

Down in HGSOC

–

miR-1908-5p was found to be an indicator of PFS

–

[13]

Ovarian cancer

15 platinum-sensitive ovarian cancer patients and 15 platinum-resistant ovarian cancer patients

Up in platinum-resistant patients

–

–

–

[25]